Projects

RNDr. Stanislava Vranková, PhD.

International

Finished
  • Effects of antioxidants on metabolic syndrome: reactive oxygen species/nitric oxide balance
    Program: Inter-institute agreement
    Duration: 1. 1. 2007 – 31. 12. 2015
  • Effect of natural polyphenols on the development and maintenance of experimental hypertension and remodelling of cardiovascular system
    Program: Inter-institute agreement
    Duration: 1. 10. 2004 – 30. 9. 2013
  • The effect of natural polyphenols on the damage of cardiovascular system and kidney indiced by long-term cyclosporine A treatment
    Program: Inter-institute agreement
    Duration: 1. 1. 2007 – 31. 12. 2010
  • Different models of experimental hypertension and their vasoactive systems
    Program: Inter-institute agreement
    Duration: 1. 1. 2005 – 31. 12. 2009
  • The effect of polyphenolic compounds on the prevention and regression of a tissue damage ba long-term cyclosporine A treatment
    Program: Inter-institute agreement
    Duration: 1. 1. 2004 – 31. 12. 2006

National

Current
  • Effects of mesenchymal stem cells and HMGB1 inhibitor on cardiovascular system after experimentally induced myocardial infarction in hypertension and diabetes mellitus
    Program: SRDA
    Duration: 1. 7. 2023 – 30. 6. 2027
Finished
  • Comparison of antidepressant effects of natural psychoplastogen and an mTOR activator in animal model of depression
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2023
  • Crosstalk of metabolic factors and neurogenic signaling in experimental models of depression
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2020
  • Interaction of nitrergic, neurotrophic and endocrine signaling in the etiopathogenesis of schizophrenia
    Program: SRDA
    Duration: 1. 7. 2015 – 30. 6. 2019
  • Nitric oxide and brain redox status in an experimental neurodevelopmental model of schizophrenia
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2017
  • Sensory information filteringin persons with genetic risk of schizophrenia
    Program: VEGA
    Duration: 1. 1. 2014 – 31. 12. 2016
  • The role of nuclear factor kappa B in experimental hypertension
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2013
  • In-vivo antioxidant gene therapy in the therapy of hypertension
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Hypertension and diabetes as the parts of metabolic syndrome: the effects of antioxidant therapy
    Program: SRDA
    Duration: 1. 6. 2008 – 31. 12. 2010
  • Modification of hypertrophy and heart failure in the model of continual light-induced hypertension in rats by melatonin and captopril
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2010
  • Epigenetic risk factors of cereberal stroke
    Program: SRDA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • Morphological and molecular changes of tissues as result of cellular damage in decompression sickness
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2008
  • Mechanism of indapamide effect on the prevention and treatment of experimental hypertension and organ damage
    Program: VEGA
    Duration: 1. 1. 2006 – 1. 12. 2008
  • Melatonine-induced modification of hypertrophy and heart failure in NO deficient hypertension
    Program: VEGA
    Duration: 1. 1. 2006 – 1. 12. 2008
  • Pharmacological treatment of hypertension in early stage of its development
    Program: VEGA
    Duration: 1. 1. 2006 – 1. 12. 2008
  • Role of bioflavonoids in prevention of social stress-induced hypertension
    Program: SRDA
    Duration: 1. 1. 2005 – 31. 12. 2007
  • Effects of mesenchymal stem cells and HMGB1 inhibitor on cardiovascular system after experimentally induced myocardial infarction in hypertension and diabetes mellitus
    Program: SRDA
    Duration: 0. 0. 0000 – 0. 0. 0000
Employees